Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
LG

LGNDStock

Nasdaq Global Market · Healthcare · US

$286.85 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment LGND's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 0 of 7 decided standards passing. AAOIFI, Dow Jones Islamic are within 3 points of their line. Even if they all crossed, the majority verdict would stay Not compliant. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 4.85% *HTR non-permissible income 5.09%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MOM · SCALP
Entry
$316.23
Stop
$313.06
Target
$322.56
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 95.7% aligned
VWAPPrice below VWAP ($295.48)
VolumeRelative volume 4.1× the 20-day average
Momentum10-day rate of change -5.6%

LGND is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

435 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$361.27
+25.9% · 11 analysts
Institutional own.
118.4% *
of shares
Momentum (10d)
-5.6%
rate of change
SMC grade
C · 55
95.7% aligned
4.85% *
Purification ratio (secondary provider, uncertain)
5.09%
Non-permissible income — HTR, from filings (2025-12-31)
C · 55
SMC grade — 95.7% timeframe alignment
-5.6%
Rate of change (10d)
$361.27
Price target (+25.9%) · 11 analysts
118.4%
Institutional ownership *

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to LGND’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $5.8B as of 2026-11-19. At the 2026-11-20 close it is about $5.6B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 20.5% (19.8% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 8.8% (8.5% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 2 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 19.81% 30.00% Pass(10.2pp buffer)
Interest-bearing investments 8.49% 30.00% Pass(21.5pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
Usmani Fail 3 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.59% 33.00% Fail(18.6pp over)
Interest-bearing investments 22.12% 33.00% Pass(10.9pp buffer)
Non-liquid assets 74.16% at least 20.00% Pass(54.2pp above the floor)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
Net liquid assets per share $77.5M under mkt cap $5.8B Pass
MSCI Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 51.59% 33.33% Fail(18.3pp over)
Cash + interest-bearing securities 22.12% 33.33% Pass(11.2pp buffer)
Accounts receivable 25.84% 33.33% Pass(7.5pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
FTSE Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 50.42% 33.33% Fail(17.1pp over)
Cash + interest-bearing securities 22.12% 33.33% Pass(11.2pp buffer)
Accounts receivable 25.84% 50.00% Pass(24.2pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
Dow Jones Islamic Market Fail 3 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 30.45% 33.00% Pass(2.6pp buffer)
Cash + interest-bearing securities 13.05% 33.00% Pass(19.9pp buffer)
Accounts receivable 2.20% 33.00% Pass(30.8pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
S&P Shariah Fail 2 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 37.96% 33.00% Fail(5.0pp over)
Cash + interest-bearing securities 16.27% 49.00% Pass(32.7pp buffer)
Accounts receivable 2.74% 49.00% Pass(46.3pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)
MSCI M-Series Fail 2 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 37.96% 33.33% Fail(4.6pp over)
Cash + interest-bearing securities 16.27% 33.33% Pass(17.1pp buffer)
Accounts receivable 19.01% 49.00% Pass(30.0pp buffer)
Non-permissible income 5.09% 5.00% Fail(0.1pp over)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Dow Jones Islamic Market (% of 24-mo avg market cap)debt ratio 2.6pts
MSCI Islamic Index (% of total assets)receivables ratio 7.5pts
AAOIFI Standard 21 (% of market cap)debt ratio 10.2pts
Usmani (% of total assets)debt ratio 18.6pts
MSCI Islamic Index (% of total assets)debt ratio 18.3pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 17.1pts

The numbers the ratios are built from

Read from LGND's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $268.1M 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $1.1B 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $494.8M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, ShortTermInvestments
Total assetsBalance sheet total $2.2B 2026-09-30 Assets
Market capDenominator for AAOIFI $5.8B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $3.0B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $3.7B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $13.7M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-10-30, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-27, period ended 2025-12-31. Screened 2026-11-19.

  • Total assets$2.2B
    Assets · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Interest-bearing debt$1.1B
    LongTermDebtNoncurrent $679.9M · period ended 2026-09-30 · 10-Q filed 2026-10-30
    LongTermDebtCurrent $448.3M · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Cash and interest-bearing securities$494.8M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents $103.4M · period ended 2026-09-30 · 10-Q filed 2026-10-30
    ShortTermInvestments $391.4M · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Receivables$83.2M
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-10-30
  • Revenue$268.1M
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-02-27
  • Interest income (non-permissible)$13.7M
    InvestmentIncomeInterest · period ended 2025-12-31 · 10-K filed 2026-02-27
  • Market cap$5.8B
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link

8 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for LGND. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-19 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

Revenue by business segment

LGND’s 10-K reports all $268.1M of its revenue for the fiscal year 2025-01-01 to 2025-12-31 under one line, Development and Licensing of Biopharmaceutical Assets, and does not break it down further.

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-27 (accession 0000886163-26-000006), read from its XBRL on SEC EDGAR.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-19.

Within 3 points of the line

AAOIFI, Dow Jones Islamic are within 3 points of their line. Even if they all crossed, the majority verdict would stay Not compliant.

The ratios that move with the share price

AAOIFI's debt ratio is $1.2B debt (operating leases included, as the screen counts it) over a market cap of $5.8B (as of 2026-11-19), 19.8% against a 30% line.

At the 2026-11-20 close the market cap is about $5.6B (the stored cap moved by the share price since), so this ratio would read 20.5%; the line is -32% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $3.8B (-34%), about $192.34 a share against $291.32 implied by the screen's own figures.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing).

At the screen's market cap, debt would have to rise by $594.0M to reach the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing, counting every standard that divides the same figure).

AAOIFI's investments ratio (8.5% against a 30% line) would only fail if the market cap fell by 72%, to $1.6B. At the 2026-11-20 close it would read 8.8%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold LGND

15 of the 252 funds whose filed holdings we currently hold own LGND shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns LGND.

You may already own it

Widely held U.S. index funds. If you own one, you own LGND through it. None of them is a Shariah fund; the last column is our look-through of each.

FundLGND in fundFund compliant by weight
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.01% 54%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.01% 54%
SCHB Schwab U.S. Broad Market ETF 0.01% 53%
Other funds
FundLGND in fundFund compliant by weight
CSMVX Congress Small Cap Growth Fund 3.89% 76%
CSMD Congress SMid Growth ETF 2.64% 67%
MNDJX MFS New Discovery Fund 2.33% 54%
GOGFX Victory Sycamore Small Company Opportunity Fund 1.38% 35%
DFDSX DF DENT SMALL CAP GROWTH FUND 1.07% 63%
ACSG American Century Small Cap Growth Insights ETF 0.50% 53%
USCAX Victory Small Cap Stock Fund 0.35% 37%
TPSC Timothy Plan US Small Cap Core ETF 0.33% 39%
TQAIX T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund 0.16% 53%
CSGEX BlackRock Advantage Small Cap Growth Fund 0.09% 49%
2 more funds
FundLGND in fundFund compliant by weight
OWTEX Old Westbury Total Equity Fund 0.08% 48%
IJSIX VY(R) JPMORGAN SMALL CAP CORE EQUITY PORTFOLIO 0.08% 39%

Sorted by LGND’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names LGND once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding LGND
InvestorFirmPositionWeightAs of
Ken Fisher Fisher Asset Management $40M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $24M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $13M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $5M 0.0% 2026-09-30
Ray Dalio Bridgewater Associates $3M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $2M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $1M 0.0% 2026-09-30
Caxton Associates Caxton Associates LLP $0M 0.0% 2026-09-30
Israel Englander Millennium Management $0M 0.0% 2026-09-30
Joel Greenblatt Gotham Asset Management $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

322.75287.47252.20216.92181.652025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
265.67
S2
275.83
S1
281.39
PIVOT
291.55
R1
297.11
R2
307.27
R3
312.83

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
277.28 – 320.80
±7.28% from 299.04, made 2026-09-26 · resolves 2026-10-03
STRONG BUY
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
2 buy · 0 neutral · 10 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)38.80NEUTRAL
Stochastic %K (14)10.31BUY
CCI (20)-192.17BUY
Williams %R (14)-89.69BUY
MACD (12,26,9)-3.40SELL
ROC (10)-6.32SELL
Momentum (10)-19.35SELL
EMA (10)299.45SELL
SMA (10)303.82SELL
EMA (20)303.32SELL
SMA (20)307.95SELL
EMA (30)303.66SELL
SMA (30)306.42SELL
EMA (50)301.64SELL
SMA (50)302.35SELL
EMA (100)291.30SELL
SMA (100)298.98SELL
EMA (200)261.25BUY
SMA (200)260.82BUY

About LGND

Healthcare · Biotechnology

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

ligand.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-09-30

MOM
Type · SCALP
316.23
Entry
313.06
Stop
322.56
Target
LOSS
Outcome · exit 313.06 (-1.00%)

Stop 313.06 Now 286.85 Target 322.56

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 64
⏰ 4H BEARISH 34
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-5.6%
Rate of change (10d)
4.1×
Volume vs its 20-day average
-2.53
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.